Nuevocor key facts
as of Oct 2026- Operator of a biotechnology firm intended to develop gene therapies for the treatment of cardiovascular disease.
- Nuevocor is valued at approximately $30.1M as of Oct 2026 (last reported valuation).
- It has raised $80.6M; the latest was Later Stage VC ($45.0M) in May 2025.
- Notable investors include EDBI, SEEDS Capital, Highlight Capital, Kurma Partners, Boehringer Ingelheim Venture Fund — 12 tracked in total.
- Status: Privately Held (backing).
Nuevocor's last reported valuation, Nov 2022. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Nuevocor: the Monday email on marks, rounds and moves
Nuevocor funding rounds
No funding rounds for Nuevocor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Nuevocor
12+Nuevocor valuation
Nuevocor's last reported valuation was $30.1 million in Nov 2022. No priced round, secondary trade or fund mark has surfaced since.
Nuevocor investors
12 investors are on record for Nuevocor, including EDBI, SEEDS Capital, Highlight Capital and Kurma Partners.
About Nuevocor
Operator of a biotechnology firm intended to develop gene therapies for the treatment of cardiovascular disease. The company focuses on genetic cardiomyopathies characterized by aberrant mechanobiology, which seeks to treat by modulating mechanical force transduction, enabling doctors to restore cardiac function in diseased hearts.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2020
- Employees
- 29
- Website
- nuevocor.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.